Medicus Pharma's SkinJect Shows 73% Clearance in Phase 2 Trial, Sets Stage for FDA Discussions
Event summary
- SkinJect Phase 2 trial achieved 73% clinical clearance in 200-µg cohort for nodular basal cell carcinoma.
- Principal Investigator Babar K. Rao to present clinical interpretation during March 26 business update.
- Company to file 2025 Form 10-K on March 25, ahead of the update call.
- SkinJect targets $2B market for non-melanoma skin diseases, including Gorlin Syndrome.
The big picture
Medicus Pharma's positive Phase 2 data for SkinJect positions the microneedle platform as a potential non-surgical alternative for basal cell carcinoma, a $2B market. The results could attract partners or buyers, especially as the company explores expanded access programs for rare diseases like Gorlin Syndrome. The upcoming FDA discussions will be critical in determining the speed of commercialization.
What we're watching
- Regulatory Pathway
- Whether Medicus can secure an EOP2 meeting with the FDA in H1 2026 to discuss SkinJect's pivotal trial design.
- Partnership Dynamics
- The pace at which Medicus advances collaborations with HelixNano and Reliant AI to expand SkinJect's applications.
- Commercialization Timing
- How quickly Medicus can translate Phase 2 data into strategic partnerships or licensing deals for SkinJect.
Related topics